AIMS Innovation is an Insight & Software Performance Analytics company with head office in Oslo. The AIMS technology originates from the internationally recognized research environment at the University of Oslo. The company is on a mission to simplify and automate Software Performance Insight across complex and connected enterprise software.
Biomolex offers new technology for autoradiography, genomics and proteomics analysis.
CardiNor commercializes Secretoneurin (SN), a new biomarker for cardiovascular disease (CVD). The use of SN for CVD is based on research carried out at Akershus University Hospital, HUS, Oslo University Hospital and Akademiska Sjukhuset in Uppsala, Sweden.
DoMore Diagnostics is a company developing new diagnostic methods based on artificial intelligence.
Elliptic Labs is creating new and intuitive ways of interacting with computers. By combining expert knowledge from multiple disciplines, such as signal processing, consumer research and interaction design, Elliptic Labs seeks to develop unique and human-centered interactions.
EpiGuard develops improved patient transport solutions to meet new global epidemic challenges.
HoloCare AS creates holographic solutions for clinical research and enhanced medical knowledge.
Lunde Lab develops interactive therapeutic games that deals with several mental health issues through engaging interactive training.
Nordic Nanovector develops novel anticancer therapeutics based on The Norwegian Radium Hospital and Nordic Nanovector’s own innovative research on tumor targeted antibody based nanovector. The first product candidate, Betalutin, for treatment of non-hodgkins lymphoma, is in clinical phase I/II trials.
Novelda AS is a privately held, R&D driven, fabless semiconductor company, based in Norway and specializing in nanoscale wireless low-power technology for ultra high resolution impulse radar
Nykode Therapeutics is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody is focusing on cancer vaccines and is partnering the technology within infection and veterinary use.
Ostomycure develops the TIES® System. With the TIESx® System the patient is provided with a permanent, patient controlled continent stoma. The TIES® System is a titanium port with lid and is implanted in place of a conventional ileostomy. This allows patients to exercise their needs when it suits them, in contrast to the conventional stoma that continually empties itself into a bag, causing discomfort, noise and smell.
Oncoinvent AS is a privately held Norwegian company. The vision of the company is to bring new treatment options to cancer patients by developing novel medical products. Delivery of tumor-cell killing doses of radiation is the main mechanism of the products of Oncoinvent AS. Radioisotopes are combined with carriers for optimal delivery.
Pharmasum Therapeutics is a Norwegian company focusing on the discovery and development of differentiated drugs for treatment of neurogical diseases, especially dementia.
Pre Diagnostics is an innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. Pre Diagnostics aims to be a leader in the diagnosis of early Alzheimer’s disease and is thus focused on the development of IVD biomarker products that use well-established technologies and procedures.
Prediktor Medical is developing a system for estimation of glucose (blood sugar) based on the combination of several noninvasive measurement principles such as advanced multivariate analysis and dynamic models for glucose/insulin interaction. The device will be body mounted in the form of a bracelet or a watch communicating with a mobile phone or a tablet for data presentation and device.
ProfMof provides world-class Metal-Organic Frameworks (MOFs) that can be applied to a wide array of industrial processes. The products have unique characteristics and provide high stability, high porosity, and functionalization.
Promons core technology is the innovative and patent pending Shield technology. It is proactive, i.e. it stops malware attacks without the need for either signatures or heuristic data, and it focuses on the vulnerabilities instead of the threats. Promon has sold the system to several larger international finance organizations.
Prophylix Pharma develops a safe new treatment that prevents excessive bleeding in fetuses and newborns caused by FNAIT. Today, such bleedings may cause life-long disabilities or death.
Prosa Security AS offers the new game changing cyber security software. Software systems and applications are today of increasing strategic importance for businesses — but they are also target for cyber-criminals. Prosa Security offers a unique solution that secures your entire software application infrastructure.
Respinor develops a medical device for respiration monitoring using ultrasound technology.
Setred provides a new unique 3D display technology that enables a full depth experience without the use of goggles or headgear. It is a plug and play device that can be used with any computer using a standard graphics card.
The founders of Somsagt AS wish to give clinicians an easier workday. Health-care personnel deserves the latest within research on how to meet and handle patients and colleagues. The company therefore builds the bridge between research and clinical practice. Through training in ” tricky patients and their relatives”, conflict management” and ”when the damage is done”, the company enables hospitals to make good medical communication to part of the culture. The teachers are all clinicians with a Ph.D.
Stily develops artificial intelligence for online stores to give their customers a more personalized experience. Customers get tailored suggestions based on their styles and personal features. Online stores get more loyal customers and less returns.
Ultimovacs AS is developing a novel peptide based therapeutic cancer vaccine. The vaccine consists of a mix of peptides which are fragments of the enzyme telomerase expressed by cancer cells allowing them to divide endlessly. The vaccine is undergoing clinical phase 1 trials.